GB2597312A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

USPTO Abstract

A Cannabidiol (CBD) preparation for use in the treatment of seizures associated with potassium channel (KCN) gene mutations. The KCN gene mutation can be in KCNA1 and/or KCNQ2. The seizures can be tonic, tonic-clonic, or absence and focal seizures with impairment. The CBD preparation can comprise 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC). The CBD preparation can be used with one or more concomitant anti-epileptic drugs (AED). The AED can be clobazam, vigabatrin, phenobarbital, diazepam, and zonisamide. The CBD can be isolated from cannabis plant material. The CBD preparation can be a synthetic preparation. The CBD preparation can be administered at a dose greater than 5 mg/kg/day or at a dose of either 20 mg/kg/day, 25 mg/kg/day, or 50 mg/kg/day. A further aspect of the invention is a method of treating seizures associated with potassium channel gene mutations by administering a CBD preparation.